<DOC>
	<DOCNO>NCT03052517</DOCNO>
	<brief_summary>This study 2-treatment period , randomize , multicenter parallel-group study . The overall purpose study provide long- term safety data fevipiprant ( QAW039 ) ( Dose 1 Dose 2 ) , compare placebo , add Global Initiative Asthma ( GINA ) step 3 , 4 , 5 standard-of-care ( SoC ) asthma therapy ( GINA 2016 ) , patient moderate-to- severe asthma .</brief_summary>
	<brief_title>Study Safety QAW039 Patients With Asthma Inadequately Controlled Standard-of-care Asthma Treatment</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients complete prior Phase 3 study QAW039 : Informed consent assent ( applicable ) . Completion Treatment Period ( blind study drug ) prior Phase 3 study QAW039 . Patient able safely continue study judge investigator . Patients previously participate study QAW039 : Written inform consent . A diagnosis asthma , uncontrolled GINA 3/4/5 asthma medication . Evidence airway reversibility airway hyper reactivity . FEV1 ≥40 % ≤85 % predict normal value . An ACQ score ≥1.5 prior enter study . Patients complete prior phase 3 study QAW039 : Pregnant nursing ( lactate ) woman . Women childbearing potential unless use basic method contraception dose study drug Patients complete Treatment Period blind study drug prior QAW039 study participate . Inability comply study requirement . Patient experience serious drugrelated AE prior QAW039 study participate . Patient develop condition prior study would exclude participation study . Patients previously participate study QAW039 : Use investigational drug within 5 halflives study entry , within 30 day , whichever longer . Subjects participate another trial QAW039 . A QTcF ( Fridericia ) ≥450 msec ( male ) ≥460 msec ( female ) . History malignancy exception local basal cell carcinoma skin Pregnant nursing ( lactate ) woman . Serious comorbidities . Patients great 20 mg simvastatin &gt; 40 mg atorvastatin , &gt; 40 mg pravastatin , &gt; 2 mg pitavastatin . Statin dose less equal dos well statin permit study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Asthma , QAW039</keyword>
</DOC>